Europeiska unionen - estniska - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatiidi ained, välja arvatud kortikosteroidid - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Estland - estniska - Ravimiamet

g.l. pharma gmbh - finasteriid - õhukese polümeerikattega tablett - 5mg 14tk; 5mg 90tk; 5mg 15tk; 5mg 20tk; 5mg 10tk; 5mg 30tk; 5mg 50tk; 5mg 100tk

Estland - estniska - Ravimiamet

zentiva k.s. - febuksostaat - õhukese polümeerikattega tablett - 120mg 28tk; 120mg 98tk; 120mg 14tk; 120mg 84tk; 120mg 42tk

Estland - estniska - Ravimiamet

sandoz pharmaceuticals d.d. - febuksostaat - õhukese polümeerikattega tablett - 120mg 28tk; 120mg 42tk; 120mg 84tk; 120mg 98tk; 120mg 56tk

Estland - estniska - Ravimiamet

teva b.v. - febuksostaat - õhukese polümeerikattega tablett - 80mg 98tk; 80mg 10tk; 80mg 14tk; 80mg 42tk; 80mg 30tk

Estland - estniska - Ravimiamet

alembic pharmaceuticals europe limited - febuksostaat - õhukese polümeerikattega tablett - 120mg 84tk; 120mg 42tk; 120mg 98tk; 120mg 28tk; 120mg 14tk

Estland - estniska - Ravimiamet

teva b.v. - febuksostaat - õhukese polümeerikattega tablett - 120mg 10tk; 120mg 14tk; 120mg 84tk; 120mg 28tk

Estland - estniska - Ravimiamet

b. braun melsungen ag - propofool - süste-/infusiooniemulsioon - 10mg 1ml 100ml 10tk; 10mg 1ml 10ml 10tk; 10mg 1ml 20ml 10tk; 10mg 1ml 100ml 1tk

Estland - estniska - Ravimiamet

zentiva k.s. - febuksostaat - õhukese polümeerikattega tablett - 80mg 42tk; 80mg 98tk; 80mg 84tk; 80mg 14tk

Estland - estniska - Ravimiamet

alembic pharmaceuticals europe limited - febuksostaat - õhukese polümeerikattega tablett - 80mg 42tk; 80mg 98tk; 80mg 84tk; 80mg 28tk; 80mg 14tk